MADRID, Spain and CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to ...
MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / March 11, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results